NEW ORLEANS--(BUSINESS WIRE)--FibroGen, Inc. today announced that administration of investigational therapy FG-3019, a human monoclonal antibody against connective tissue growth factor (CTGF), reversed the process of fibrosis in a preclinical model of radiation-induced lung fibrosis, a finding that has implications for treating multiple types of fibrotic disease. Administration of FG-3019 was also found to improve lung function and survival in this model. The data were presented at the International Conference of the American Thoracic Society in New Orleans (Abstract #A1054).
